Kura Oncology, Inc.

This early-stage study tests a new drug called KO-2806 in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and see if the drug can shrink tumors when used alone or with other cancer medicines. About 300 participan…

This early-stage trial tests a new oral drug called ziftomenib combined with imatinib in adults with advanced gastrointestinal stromal tumors (GIST) that have stopped responding to imatinib alone. The study will enroll about 157 people to see if the combination is safe and can sh…

This early-stage study tests a new drug called ziftomenib combined with standard treatments for people with a type of acute myeloid leukemia (AML) that has come back or not responded to therapy. The main goal is to check safety and find the best dose. About 171 adults with specif…

This study tests if adding an experimental drug called ziftomenib to standard chemotherapy helps people with a specific genetic type of acute myeloid leukemia (AML) live longer or achieve remission. About 1,300 adults with untreated AML and certain gene changes will receive eithe…

This early-stage study tests an experimental drug called ziftomenib added to usual treatments for acute myeloid leukemia (AML) in people with specific gene changes (NPM1 mutation or KMT2A rearrangement). About 420 adults with newly diagnosed or returning AML will receive ziftomen…